✦ LIBER ✦

Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent crohn's disease

✍ Scribed by Yacyshyn, Bruce R.; Chey, W.; Goff, J.; Salzberg, B.; Buchman, A.; Baerg, R.; Anderson, F.; Koval, G.; Barish, C.; Safdi, M.; Rutgeerts, P.; Shanahan, William

Book ID: 123210479
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 175 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(00)84415-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, placebo-controlled trial o

A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels

✍ Yacyshyn, Bruce R.; Chey, W.Y.; Goff, J; Salzberg, B; Baerg, R; Buchman, A.L.; T 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 341 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human anti body to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease

✍ Feagan, Brian G.; Sandborn, William J.; Baker, J.P.; Cominelli, F.; Sutherland, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 165 KB